免疫治疗在实体瘤中的应用现状

doi:10.11904/j.issn.1002-3070.2024.01.009

Abstract

Abstract: Cancer immunotherapy has great potential and is expected to become the mainstream method of cancer treatment.In the current application of cancer immunotherapy,immune checkpoint inhibitors(ICIs)have achieved remarkable results.The currently widely used ICIs in clinical practice include inhibitors targeting cytotoxic T lymphocyte-associated antigen-4(CTLA-4),programmed death-1(PD-1)and programmed death-ligand 1(PD-L1).In addition,new immunotherapies such as oncolytic viruses and chimeric antigen receptor T cells are gradually entering the clinical practice,and combination therapy related to ICIs has shown unique advantages.This article will focus on the current application status of ICIs,oncolytic viruses,and chimeric antigen receptor T cell therapies in solid tumors either their individual or combined forms.

Key words: Immunotherapy, Immune checkpoint inhibitors, Oncolytic virus therapy, Chimeric antigen receptor T cell therapy

CLC Number:

R730.3

ZHAO Lu, ZHANG Zhengfeng, WANG Dazhen, YANG Liu, LIU Ze, LOU Changjie. The current application status of immunotherapy in solid tumors[J]. Journal of Practical Oncology, 2024, 38(1): 55-61.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2024.01.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2024/V38/I1/55

References

1 Wang SJ,Dougan SK,Dougan M.Immune mechanisms of toxicity from checkpoint inhibitors[J].Trends Cancer,2023,9(7):543-553.
2 Jiang Y,Chen M,Nie H,et al.PD-1 and PD-L1 in cancer immunotherapy:clinical implications and future considerations[J].Hum Vaccin Immunother,2019,15(5):1111-1122.
3 Linsley PS,Brady W,Grosmaire L,et al.Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation[J].J Exp Med,1991,173(3):721-730.
4 Kang SP,Gergich K,Lubiniecki GM,et al.Pembrolizumab KEYNOTE-001:an adaptive study leading to accelerated approval for two indications and a companion diagnostic[J].Ann Oncol,2017,28(6):1388-1398.
5 Raedler LA.Keytruda(pembrolizumab):First PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma[J].Am Health Drug Benefits,2015,8:96-100.
6 Burtness B,Harrington KJ,Greil R,et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048):a randomised,open-label,phase 3 study[J].Lancet,2019,394(10212):1915-1928.
7 Fuchs CS,Doi T,Jang RW,et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:Phase 2 clinical KEYNOTE-059 trial[J].JAMA Oncol,2018,4(5):e180013.
8 Marcus L,Lemery SJ,Keegan P,et al.FDA approval summary:pembrolizumab for the treatment of microsatellite instability-high solid tumors[J].Clin Cancer Res,2019,25(13):3753-3758.
9 Chung HC,Ros W,Delord JP,et al.Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer:results from the phase II KEYNOTE-158 study[J].J Clin Oncol,2019,37(17):1470-1478.
10 Borcoman E,Le Tourneau C.KEYNOTE-158 study,FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer[J].Ann Transl Med,2020,8(23):1611.
11 Vuky J,Balar AV,Castellano D,et al.Long-term outcomes in KEYNOTE052:Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer[J].J Clin Oncol,2020,38(23):2658-2666.
12 Schmid P,Salgado R,Park YH,et al.Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk,early-stage triple-negative breast cancer:results from the phase 1b open-label,multicohort KEYNOTE -173 study[J].Ann Oncol,2020,31(5):569-581.
13 Marabelle A,Fakih M,Lopez J,et al.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab:prospective biomarker analysis of the multicohort,open-label,phase 2 -KEYNOTE158 study[J].Lancet Oncol,2020,21(10):1353-1365.
14 O′malley DM,Bariani GM,Cassier PA,et al.Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer:results from the KEYNOTE-158 study[J].J Clin Oncol,2022,40(7):752-761.
15 Pavri SN,Clune J,Ariyan S,et al.Malignant melanoma:beyond the basics[J].Plast Reconstr Surg,2016,138(2):330-340.
16 Rizvi NA,Mazières J,Planchard D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer(CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.
17 Motzer RJ,Rini BI,Mcdermott DF,et al.Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma:extended follow-up of efficacy and safety results from a randomised,controlled,phase 3 trial[J].Lancet Oncol,2019,20(10):1370-1385.
18 Johnson DE,Burtness B,Leemans CR,et al.Head and neck squamous cell carcinoma[J].Nat Rev Dis Primers,2020,6(1):92.
19 Overman MJ,Mcdermott R,Leach JL,et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer(CheckMate 142):an open-label,multicentre,phase 2 study[J].Lancet Oncol,2017,18(9):1182-1191.
20 Tawbi HA,Schadendorf D,Lipson EJ,et al.Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma[J].N Engl J Med,2022,386(1):24-34.
21 Forde PM,Spicer J,Lu S,et al.Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J].N Engl J Med,2022,386(21):1973-1985.
22 Doki Y,Ajani JA,Kato K,et al.Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma[J].N Engl J Med,2022,386(5):449-462.
23 Migden MR,Rischin D,Schmults CD,et al.PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma[J].N Engl J Med,2018,379(4):341-351.
24 Keeping S,Xu Y,Chen CI,et al.Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma[J].Future Oncol,2021,17(5):611-627.
25 Markham A.Atezolizumab:first global approval[J].Drugs,2016,76(12):1227-1232.
26 Herbst RS,Giaccone G,De Marinis F,et al.Atezolizumab for first-line treatment of PD-L1-selected patients with nsclc[J].N Engl J Med,2020,383(14):1328-1339.
27 Mathieu L,Shah S,Pai-Scherf L,et al.FDA approval summary:atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer[J].Oncologist,2021,26(5):433-438.
28 Gutzmer R,Stroyakovskiy D,Gogas H,et al.Atezolizumab,vemurafenib,and cobimetinib as first-line treatment for unresectable advanced braf(v600)mutation-positive melanoma(imspire150):primary analysis of the randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2020,395(10240):1835-1844.
29 Finn RS,Qin S,Ikeda M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J].N Engl J Med,2020,382(20):1894-1905.
30 Syed YY.Durvalumab:First global approval[J].Drugs,2017,77(12):1369-1376.
31 Johnson ML,Cho BC,Luft A,et al.Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer:the phase III poseidon study[J].J Clin Oncol,2023,41(6):1213-1227.
32 Rimini M,Fornaro L,Lonardi S,et al.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer:an early exploratory analysis of real-world data[J].Liver Int,2023,43(8):1803-1812.
33 Walker JW,LebbéC,Grignani G,et al.Correction:efficacy and safety of avelumab treatment in patients with metastatic merkel cell carcinoma:experience from a global expanded access program[J].J Immunother Cancer,2020,8(1):e000313.
34 Apolo AB,Ellerton JA,Infante JR,et al.Avelumab as second-line therapy for metastatic,platinum-treated urothelial carcinoma in the phase Ib javelin solid tumor study:2-year updated efficacy and safety analysis[J].J Immunother Cancer,2020,8(2):e001246.
35 Callahan MK,Wolchok JD.At the bedside:CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy[J].J Leukoc Biol,2013,94(1):41-53.
36 Lisi L,Lacal PM,Martire M,et al.Clinical experience with CTLA-4 blockade for cancer immunotherapy:from the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment[J].Pharmacol Res,2022,175:105997.
37 Nikoo M,Rabiee F,Mohebbi H,et al.Nivolumab plus ipilimumab combination therapy in cancer:current evidence to date[J].Int Immunopharmacol,2023,117:109881.
38 Ribas A,Wolchok JD.Cancer immunotherapy using checkpoint blockade[J].Science,2018,359(6382):1350-1355.
39 Garassino MC,Gadgeel S,Speranza G,et al.Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer:5-year outcomes from the phase 3 KEYNOTE-189 study[J].J Clin Oncol,2023,41(11):1992-1998.
40 Negrao MV,Lam VK,Reuben A,et al.PD-L1 expression,tumor mutational burden,and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer[J].J Thorac Oncol,2019,14(6):1021-1031.
41 Mansfield AS,Ka·zarnowicz A,Karaseva N,et al.Safety and patient-reported outcomes of atezolizumab,carboplatin,and etoposide in extensive-stage small-cell lung cancer(IMpower133):A randomized phase I/III trial[J].Ann Oncol,2020,31(2):310-317.
42 Antonia SJ,Villegas A,Daniel D,et al.Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer[J].N Engl J Med,2017,377(20):1919-1929.
43 Xu Y,Li H,Fan Y.Progression patterns,treatment,and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer[J].Front Oncol,2021,11:642883.
44 Hong M,Clubb JD,Chen YY.Engineering CAR-T cells for next-generation cancer therapy[J].Cancer Cell,2020,38(4):473-488.
45 Meng Y,Deng B,Rong L,et al.Short-interval sequential CAR-T cell infusion may enhance prior CAR-T cell expansion to augment anti-lymphoma response in B-NHL[J].Front Oncol,2021,11:640166.
46 Zhang Y,Wang Y,Liu Y,et al.Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma:a single-arm,phase 1-2 trial[J].Leukemia,2022,36(1):189-196.
47 Li W,Qiu S,Chen J,et al.Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy[J].Immunity,2020,53(2):456-470.
48 Edeline J,Houot R,Marabelle A,et al.CAR-T cells and bites in solid tumors:Challenges and perspectives[J].J Hematol Oncol,2021,14(1):65.
49 Brown CE,Alizadeh D,Starr R,et al.Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J].N Engl J Med,2016,375(26):2561-2569.
50 Louis CU,Savoldo B,Dotti G,et al.Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J].Blood,2011,118(23):6050-6056.
51 Van Bruggen JaC,Martens AWJ,Fraietta JA,et al.Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+)Tcells and impede CAR-T cell efficacy[J].Blood,2019,134(1):44-58.
52 Macedo N,Miller DM,Haq R,et al.Clinical landscape of oncolytic virus research in 2020[J].J Immunother Cancer,2020,8(2):e001486.
53 Xiao Y,Yu D.Tumor microenvironment as a therapeutic target in cancer[J].Pharmacol Ther,2021,221:107753.
54 Turley SJ,Cremasco V,Astarita JL.Immunological hallmarks of stromal cells in the tumour microenvironment[J].Nat Rev Immunol,2015,15(11):669-682.
55 Ma R,Li Z,Chiocca EA,et al.The emerging field of oncolytic virus-based cancer immunotherapy[J].Trends Cancer,2023,9(2):122-139.
56 Arcangeli S,Mestermann K,Weber J,et al.Overcoming key challenges in cancer immunotherapy with engineered t cells[J].Curr Opin Oncol,2020,32(5):398-407.
57 Springuel L,Lonez C,Alexandre B,et al.Chimeric antigen receptor-T cells for targeting solid tumors:Current challenges and existing strategies[J].BioDrugs,2019,33(5):515-537.
58 Zhao Z,Condomines M,Van Der Stegen SJC,et al.Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR-T cells[J].Cancer Cell,2015,28(4):415-428.
59 Pikor LA,Bell JC,Diallo JS.Oncolytic viruses:exploiting cancer′s deal with the devil[J].Trends Cancer,2015,1(4):266-277.
60 Ajina A,Maher J.Prospects for combined use of oncolytic viruses and CAR-T cells[J].J Immunother Cancer,2017,5(1):90.
61 Moon EK,Wang LS,Bekdache K,et al.Intra-tumoral delivery of cxcl11 via a vaccinia virus,but not by modified T cells,enhances the efficacy of adoptive t cell therapy and vaccines[J].Oncoimmunology,2018,7(3):e1395997.
62 Watanabe K,Luo Y,Da T,et al.Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses[J].JCI Insight,2018,3(7):e99573.
63 Topalian SL,Hodi FS,Brahmer JR,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med,2012,366(26):2443-2454.

[1]	CHU Sitong, XU Qingyong. Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 449-453.
[2]	LU Hongnan, XIA Bingshu, QIAO Kun, ZHANG Shiyuan, HUANG Yuanxi, LU Xiangshi. Relationship between GAS1,immunotherapy and drug sensitivity in breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 351-359.
[3]	LI Fucheng, JIA Siyuan, BA Yuling, LUO Danli, XIAO Min. Research progress of immune checkpoint inhibitors in neoadjuvant therapy of early breast cancer [J]. Journal of Practical Oncology, 2023, 37(4): 367-371.
[4]	LI Juan, LIU Jiaren. The current research status and progress of immunotherapy for gastric cancer [J]. Journal of Practical Oncology, 2023, 37(4): 372-376.
[5]	LI Luqiao, ZOU Zhengyun. Current status of advanced research on immunotherapy for malignant melanoma [J]. Journal of Practical Oncology, 2023, 37(2): 144-148.
[6]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[7]	YANG Ju, LIU Qin, LIU Baorui, WEI Jia. Gastric cancer-associated cancer-testis antigen screening and immune infiltration analysis [J]. Journal of Practical Oncology, 2022, 36(6): 495-501.
[8]	GONG Ruining, REN He. Research progress and prospect of immunotherapy for pancreatic ductal adenocarcinoma [J]. Journal of Practical Oncology, 2022, 36(6): 502-506.
[9]	CAO Wenjie, WEI Yuan, KUANG Dongming. Tumor infiltrating B cells and immunotherapies [J]. Journal of Practical Oncology, 2022, 36(6): 507-512.
[10]	ZHANG Yue, WANG Yue, WEI Jia. The value of SHP2 as an anti-tumor therapeutic target and its application in tumor immunotherapy [J]. Journal of Practical Oncology, 2022, 36(6): 513-519.
[11]	CHENG Siyuan, HAN Zihan, GUO Xiaohuan, SHEN Lin, PENG Zhi. Research progress on the relationship between gut microbiota and therapeutic efficacy, and adverse reactions [J]. Journal of Practical Oncology, 2022, 36(6): 520-525.
[12]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.
[13]	LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(5): 463-467.
[14]	DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 351-355.
[15]	TONG Manlin, SHANG Ruru, LIU Xiaohong. Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme [J]. Journal of Practical Oncology, 2022, 36(3): 278-282.

The current application status of immunotherapy in solid tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments